Preclinical characterization of CYT387: a potent and selective dual inhibitor of JAK1/JAK2

The recent identification of an activating mutation of JAK2 (V617F) in >95% of Polycythemia Vera (PV) patients, and ca. 50% of Essential thrombocythemia (ET) and Myelofibrosis patients has initiated much interest in the discovery and development of selective JAK2 inhibitors as a potential targeted treatment for this patient population. This poster describes a selection of preclinical data for the novel JAK2 inhibitor CYT387 discovered in our laboratories, which is now in clinical trials for the treatment of myelofibrosis.